Kailera Therapeutics

Update in progress

KLRA (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Kailera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on obesity and related metabolic diseases. Its portfolio spans clinical and preclinical assets across injectable peptides, oral peptides, and oral small molecules. Programs include KAI-9531, an injectable GLP-1/GIP dual agonist; KAI-7535, an oral GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon tri-agonist. Based in Waltham, MA, founded in 2024, Kailera holds exclusive global rights for four metabolic assets outside Greater China.

Company score

Sentiment: 0.36; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.22; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.06; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.22; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive